HPC2 variants and screen-detected prostate cancer

Am J Hum Genet. 2001 Apr;68(4):912-7. doi: 10.1086/319502. Epub 2001 Mar 14.

Abstract

Two studies have reported significant associations between susceptibility to prostate cancer and two common missense variants of the HPC2/ELAC2 gene, with estimated relative risks in the range of two- to threefold. We investigated whether these polymorphisms could be informative in the prediction of the presence of prostate cancer in men undergoing prostatic biopsy for the evaluation of an elevated serum-PSA level (> or = 4.0 ng/ml). We genotyped 944 men who underwent a prostate biopsy at our institution, as well as a control population of 922 healthy, unselected women from the same population. The prevalence of the HPC2 Ala541Thr allele was similar in men with prostate cancer (6.3%), men with other prostatic conditions (6.8%), and healthy women (6.3%) (P = .83). We conclude that HPC2 genotyping is unlikely to be a useful adjunct to PSA in the prediction of the presence of biopsy-detected prostate cancer in asymptomatic men.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alleles
  • Amino Acid Substitution / genetics
  • Biopsy
  • Case-Control Studies
  • Continental Population Groups / genetics
  • Female
  • Gene Frequency / genetics
  • Genetic Predisposition to Disease / genetics
  • Genetic Testing*
  • Genetic Variation / genetics*
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Proteins / genetics*
  • Polymorphism, Genetic / genetics*
  • Prostate / metabolism
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology

Substances

  • ELAC2 protein, human
  • Neoplasm Proteins
  • Prostate-Specific Antigen